26 results about "SCC - Squamous cell carcinoma" patented technology

This invention discloses a lipid nanoparticle co-delivery system based on phenolic hydroxyl lipids and a manganese adjuvant. Addressing the shortcomings of traditional HPV therapeutic peptide vaccines—weak immunogenicity, easy degradation and inactivation in vivo, low bioavailability of manganese ion adjuvants making spatiotemporal co-delivery with antigens, and poor encapsulation efficiency and insufficient biosafety of conventional lipid nanocarriers—this invention constructs an integrated nanovaccine delivery system by embedding phenolic hydroxyl functional lipids into a nanocarrier framework, synergistically loading HPV E6 / E7 specific antigen peptides and manganese ion immune adjuvants. This system achieves efficient delivery, immune activation, and anti-tumor efficacy, integrating the functions of efficient antigen delivery, potent immune activation, and precise anti-tumor action. The preparation process is simple and exhibits excellent stability, overcoming the limitations of traditional HPV peptide vaccines with poor efficacy when used alone. It has broad research value and clinical translation prospects in the field of precision immunotherapy for HPV-related cervical cancer, head and neck squamous cell carcinoma, and other malignant tumors.

The application belongs to the technical field of biological medicine, and particularly relates to application of long-chain non-coding RNA expression inhibition in esophageal cancer ferroptosis inducer sensitization. The application first reveals dynamic change of long-chain non-coding RNA ENSG00000250658 in esophageal squamous cell carcinoma metastasis based on single-cell sequencing data, detects expression of ENSG00000250658 in esophageal squamous cell carcinoma tissue and correlation with prognosis by using LNA probe-based RNA in-situ hybridization technology, and first finds that knocking down ENSG00000250658 can increase killing effect of ferroptosis inducer on esophageal squamous cell carcinoma cells. Therefore, the application provides a new technical scheme and thought for clinical diagnosis and treatment of esophageal cancer.

The present application belongs to the technical field of medicine, and particularly relates to albumin nanoparticles co-loading paclitaxel and BMS-202, a preparation method and application thereof. The present application comprises a carrier and a delivery carrier loaded with drugs; comprises a carrier and drugs loaded by a delivery carrier; the drugs are paclitaxel and an inhibitor BMS-202 co-loaded with paclitaxel, and the delivery carrier is human serum albumin. The present application comprises the following steps: step 1: paclitaxel and the inhibitor BMS-202 are dissolved in an organic solvent as an organic phase; step 2: human serum albumin is dissolved in water as an aqueous phase; step 3: the organic phase is directly added to the aqueous phase, and after mixing, ultrasonic treatment is immediately performed to make the system form a nanoparticle suspension; step 4: the nanoparticle suspension is subjected to purification treatment to remove the organic solvent and unencapsulated drugs, and albumin nanoparticles co-loading paclitaxel and BMS-202 are obtained. The present application is applied to the preparation of esophageal squamous cell carcinoma drugs. Compared with the prior art, the present application is relatively effective and safe in the treatment of esophageal cancer.

The application discloses radix sophorae tonkinensis polysaccharide STGP-1, a preparation method thereof and pharmaceutical use for treating lung squamous carcinoma, and relates to the technical field of medicines. The monosaccharide composition of STGP-1 includes fucose Fuc, arabinose Ara, galactose Gal, glucose Glc, xylose Xyl and mannose Man, and the molar ratio is 0.34:12.15:25.76:57.07:1.06:3.62. The STGP-1 is obtained by extraction, separation and purification from dried roots and rhizomes of radix sophorae tonkinensis, and the preparation method comprises the steps of pretreatment and crude extraction, impurity removal treatment, anion exchange column chromatography separation, gel column chromatography purification and the like. The STGP-1 can be used alone or in combination with anti-PD-1 monoclonal antibody for preparing a medicine for treating lung squamous carcinoma. The preparation process is stable, the source is natural, and the STGP-1 can provide a new high-efficiency and low-toxicity candidate medicine for immune combined treatment of lung squamous carcinoma.

The application provides a laryngeal squamous cell carcinoma prognosis gene methylation marker and application thereof, and relates to the technical field of clinical medicine. The methylation marker is CORO1C and MAPK11, and a recurrence risk prediction model is constructed based on the two sites. The prediction model is independent of factors such as stage, age and differentiation of patients, proving the independence and universality of the prediction model. Through the RRBS technology, the methylation changes of the genes can be comprehensively analyzed at high resolution, and the prognosis value of the markers in laryngeal squamous cell carcinoma is verified. Compared with traditional single clinical pathological indicators, the methylation marker based on the molecular level provided by the application has high accuracy and sensitivity, and can provide more accurate basis for the recurrence prediction of laryngeal squamous cell carcinoma.

This invention belongs to the field of pharmaceutical formulation technology, and particularly relates to a pharmaceutical formulation for inhibiting esophageal squamous cell carcinoma metastasis and its preparation method. The preparation method of the pharmaceutical formulation for inhibiting esophageal squamous cell carcinoma metastasis includes the following steps: S1. Dissolving paclitaxel, cyperene, and a glyceryl stearate derivative in an organic solvent to obtain an oil phase; S2. Dissolving soybean lecithin and Tween 80 in water to obtain an aqueous phase; S3. Mixing the oil phase and the aqueous phase at 70-75°C, stirring to emulsify, cooling to room temperature, and freeze-drying to obtain the final product. This invention loads paclitaxel and cyperene into a nanodelivery system, constructing a pharmaceutical formulation that can both enhance antitumor effects and achieve precise and efficient mucosal delivery via oral administration, which has significant clinical significance and application prospects.

The application discloses a novel radionuclide therapeutic drug targeting nucleolus DDX24 helicase and a preparation method and application thereof. 64 The Cu-DOTA-TDP-2 has good tumor targeting uptake specificity, and is expected to provide a precise molecular imaging method for esophageal squamous cell carcinoma and other DDX24 high-expression malignant tumors; the novel radionuclide targeted drug 177 The Lu-DOTA-TDP-2 has high radiochemical yield and specific activity, good chemical stability, high affinity for DDX24 helicase, and a simple and easy-to-operate preparation method, and can be used for the treatment of DDX24 high-expression malignant tumors; the novel radionuclide targeted drug 177 The Lu-DOTA-TDP-2 has excellent biological safety performance and good tumor inhibition effect in esophageal squamous cell carcinoma and other DDX24 high-expression malignant tumors.

This invention discloses a prognostic model and construction method for cervical squamous cell carcinoma, belonging to the fields of bioinformatics and oncology. The construction method is based on a set of genes related to programmed cell death, integrating multi-omics data of cervical squamous cell carcinoma patients from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and the Cancer Genome Characterization Project (CGCI). After standardized preprocessing, differential expression analysis, bootstrap resampling combined with univariate Cox regression for initial screening, consensus screening using multiple machine learning algorithms, and finally, multivariate Cox proportional hazards regression analysis to identify three core independent prognostic genes and construct a risk scoring model. This model has undergone multi-dimensional validation and optimization, demonstrating robust predictive performance. The method of this invention is standardized and highly reproducible, and the constructed model has high accuracy and strong generalization ability, providing a reliable tool for individualized prognostic assessment and clinical decision-making for cervical squamous cell carcinoma patients.

The application discloses application of a pathogenic transposable element pL1HS as a lung squamous carcinoma biomarker and a therapeutic target. The 5'-UTR region of the pathogenic transposable element pL1HS has a nucleic acid sequence as shown in SEQ ID NO. 1, and specific detection primers are shown in SEQ ID NO. 2 and SEQ ID NO. 3 respectively. Animal experiments prove that the combined application of the reverse transcription transposition inhibitor nevirapine and the cGAS inhibitor can significantly inhibit the growth of lung squamous carcinoma. The pathogenic transposable element pL1HS can be used as a novel molecular marker in the diagnostic application dimension, and provides a precise detection index for early screening, pathological typing and prognosis judgment of lung squamous carcinoma. In the treatment application dimension, the target intervention strategy for pL1HS, especially the combined medication scheme of multi-pathway inhibitors, opens up a new direction.

The present application relates to the field of pharmaceutical preparations, and particularly relates to application of NQO1 as a target point in preparation of a drug for head and neck squamous cell carcinoma. The present application finds that NQO1 is specifically highly expressed in HNSCC tumor cells, the expression level thereof is significantly negatively correlated with an adverse prognosis of a patient, and NQO1 not only promotes proliferation, migration and in-vivo tumorigenic ability of HNSCC cells, but also participates in regulation of a bithionol death process, which indicates that the NQO1 gene can be used as a key target point for enhancing immunotherapy of HNSCC tumors. In addition, compared with a single-drug treatment group, tumor growth of a mouse in a 'doubled coumarin + anti-PD-L1 antibody' combined treatment group is most effectively inhibited, and the tumor volume and weight are significantly reduced, which first proves that targeted inhibition of NQO1 can significantly sensitize PD-1 / PD-L1 immune checkpoint blocking therapy, and a significant immune synergistic effect is realized in head and neck squamous cell carcinoma. The finding provides an innovative combined treatment strategy and a precise intervention target point for overcoming current clinical problems such as a low response rate and easy drug resistance in immunotherapy of head and neck squamous cell carcinoma.

This invention relates to the pharmaceutical applications of MRPS7 as a diagnostic biomarker for non-small cell lung cancer (NSCLC) and its inhibitors, belonging to the field of biomedical technology. For the first time, this invention utilizes immunohistochemical analysis of tumor tissues from NSCLC patients and paired adjacent normal tissues to confirm that MRPS7 protein is significantly overexpressed in NSCLC tissues (p<0.001), and this difference is statistically significant in both lung adenocarcinoma and lung squamous cell carcinoma subtypes. Furthermore, this invention demonstrates through in vitro functional experiments that knocking down MRPS7 gene expression using siRNA targeting MRPS7 significantly inhibits the proliferation, migration, and invasion abilities of NSCLC cells (A549, SK-MES-1) (p<0.001). Therefore, reagents for detecting MRPS7 expression levels can be used to prepare NSCLC diagnostic products, and MRPS7 inhibitors can be used to prepare drugs for treating NSCLC. This invention provides a novel molecular biomarker for the diagnosis of NSCLC and a new strategy for targeted therapy of NSCLC.

The application relates to the technical field of biological medicine, and particularly discloses application of SHP-1 agonist SC-43 in preparation of a medicine for treating esophageal squamous cell carcinoma, a structural formula of the SHP-1 agonist SC-43 is as follows: the medicine has a mechanism of action for treating esophageal squamous cell carcinoma, which includes direct cytotoxicity and / or immune microenvironment regulation; the medicine comprises a therapeutically effective amount of the SHP-1 agonist SC-43 and a pharmaceutically acceptable carrier. The application discloses a new use of the SHP-1 agonist SC-43, and relates to application of SC-43 in preparation of the medicine for treating esophageal squamous cell carcinoma, which provides a brand-new and effective treatment strategy for refractory tumors ESCC.

This invention relates to a methylation site marker for assisting in the early diagnosis of esophageal squamous cell carcinoma and its application, belonging to the field of biomedical technology. The methylation site marker is one or a combination of methylation sites cg05064044, cg03395511, and cg21548813 in human peripheral blood mononuclear cells, with nucleotide sequences shown in SEQ ID NO. 1-3. This invention uses methylation chip detection to find that the methylation levels of cg05064044, cg03395511, and cg21548813 in peripheral blood mononuclear cells of esophageal squamous cell carcinoma patients were significantly higher than those in healthy controls. Further analysis revealed that the methylation levels of cg05064044, cg03395511, and cg21548813 in PBMCs of esophageal squamous cell carcinoma patients in both the training and validation cohorts were significantly higher than those in healthy controls. Finally, ROC curve analysis confirmed that the three methylation sites cg05064044, cg03395511, and cg21548813 have good specificity and sensitivity, and have high diagnostic efficacy when used alone or in combination for the diagnosis of esophageal squamous cell carcinoma. They can be used as potential molecular markers for the diagnosis of esophageal squamous cell carcinoma.

The application relates to an oral squamous cell carcinoma auxiliary chemical immunotherapy response method and device, which comprises the following steps: acquiring image data and baseline clinical factors of a target user, the image data comprising metabolic parameters and image features of a tumor region; performing clinical parameter standardization processing on the metabolic parameters to obtain a standardized metabolic parameter set related to treatment response; performing stability screening on the image features by using an intragroup correlation coefficient to obtain key features related to treatment response; performing regression analysis on the baseline clinical factors to identify independent prognostic factors related to treatment response in the baseline clinical factors; and performing feature fusion on the standardized metabolic parameter set, the key features and the independent prognostic factors to obtain a response rate and a prognosis prediction result of the target user. The method can more accurately and comprehensively predict the response rate and the prognosis of the target user to the auxiliary chemical immunotherapy.

The application discloses an esophageal squamous cell carcinoma early cancer auxiliary diagnosis system based on deep learning, which comprises an esophagoscope image acquisition subsystem, a cloud platform server and a client; the esophagoscope image acquisition subsystem is used to acquire esophagoscope images and transmit the images to the cloud platform server; the cloud platform server comprises a data storage module, a data service processing module and a computing service module, and the computing service module comprises an image quality judgment model based on a deep learning network, an esophageal lesion state detection model and an early cancer grading detection model. The application can solve the missed detection problem caused by uneven doctor level in traditional esophageal squamous cell carcinoma examination, the esophageal lesion state detection model with a bilinear pooling and attention fusion mechanism can identify a lesion site, the early cancer grading detection model constructed by a lightweight residual network with a fusion attention mechanism can realize the grading of esophageal squamous cell carcinoma early cancer, and thus a simple and easy-to-use esophageal squamous cell carcinoma early cancer auxiliary diagnosis platform based on deep learning is formed.

The application belongs to the technical field of biological pharmacy, discloses application of RING1 in inhibition of esophageal squamous cell carcinoma metastasis through ubiquitination degradation of Integrin alpha 5, and provides application of a RING1 activator in preparation of a drug for treating metastatic esophageal squamous cell carcinoma. The application systematically evaluates the inhibiting effect of RING1 on esophageal squamous cell carcinoma metastasis through in-vitro cell experiments and a mouse in-vivo metastasis model; the results show that RING1 inhibits the activation of the FAK signal pathway by mediating K11 type ubiquitination degradation of Integrin alpha 5, and then inhibits the adhesion, migration ability and in-vivo metastasis ability of ESCC cells.

This disclosure provides anti-ULBP2 antibodies or antigen-binding fragments thereof (including bispecific ones). These antibodies are administered in combination with chemotherapy agents, radiotherapy, and / or immune checkpoint inhibitors for the treatment of basal squamous cell carcinoma. This disclosure also relates to methods and kits for detecting susceptibility to ULBP2-related disorders, determining their risk, and guiding treatment.

The application discloses application of an RNA editing enzyme ADAR1 in prediction of esophageal squamous cell carcinoma immunotherapy effect, and belongs to the technical field of immunotherapy.The technical problem to be solved by the application is how to predict the esophageal squamous cell carcinoma immunotherapy effect.The application provides application of a biomarker or a substance for detecting the biomarker in prediction or auxiliary prediction of immunosingle-drug treatment esophageal squamous cell carcinoma efficacy or preparation of a product for predicting or auxiliary prediction of immunosingle-drug treatment esophageal squamous cell carcinoma efficacy, and the biomarker is ADAR1 protein.Experiments prove that ADAR1 may have the potential to predict the immunosingle-drug treatment efficacy of esophageal squamous cell carcinoma.

The application discloses application of IMMU-132 and IACS010759 in preparation of an anti-esophageal squamous carcinoma drug and related drugs, relates to the technical field of biological medicine, and the combined drug comprises IMMU-132 and IACS010759. The IMMU-132 and IACS010759 are synergistically combined, PI3K-AKT-mTOR signal pathways are inhibited, and thus, ESCC cell proliferation is inhibited; the combined drug increases the intracellular ROS level and destroys the mitochondrial membrane potential, and thus, the apoptosis of cells in the mitochondrial pathway is synergistically induced. The IMMU-132 and IACS010759 provided by the application exhibit a significant synergistic anti-tumor effect, the PI3K-AKT-mTOR survival signal pathway is inhibited, and thus, the apoptosis of cancer cells is triggered, and the problems of limited curative effect and easy drug resistance of an existing ESCC treatment scheme are reduced, so that a new strategy is provided for clinic.

This application provides a method for establishing and applying mouse gastric squamous cell carcinoma cell lines and gastric cancer-related fibroblast cell lines. The culture medium for culturing these cell lines comprises L-WRN cell culture supernatant, and 100×N-2 additive (0.5 vol%–1.5 vol%), 50× vitamin A-free B-27 additive (1.5 vol%–2.5 vol%), N-acetylcysteine ​​amide (1 mM–1.5 mM), nicotinamide (8 mM–12 mM), FGF-10 (80 ng / mL–120 ng / mL), EGF (40 ng / mL–60 ng / mL), A83-01 (0.8 μM–1.2 μM), Y-27632 dihydrochloride (8 μM–12 μM), Glutamax additive (0.5 vol%–1.5 vol%), and Matrigel. The culture medium provided in this application contains 5 vol%–7 vol% Hepes buffer (8 mM–12 mM) and gastrin (0.8 nM–1.2 nM). This medium can significantly improve the success rate of in vitro culture of primary cell lines. The mouse gastric squamous cell carcinoma cell lines and gastric cancer-related fibroblast cell lines obtained from this medium are genetically stable and can be used to construct ectopic or orthotopic implantation models in immune-active mice.

The application provides a lung squamous carcinoma organoid culture medium and a culture method, the lung squamous carcinoma organoid culture medium is composed of R-spondin-1, Noggin, EGF, FGF10, FGF7, A83-01, Y-27632, Nicotinamide, Insulin, B27 Supplement, N-Acetylcysteine, Alpelisib, GlutaMAX, primary cell antibiotic and the like. The lung squamous carcinoma organoid culture medium can efficiently culture lung squamous carcinoma tissues and successfully obtain organoids, the formed organoids are highly similar to primary lung squamous carcinoma tissues in cell type, polarity and spatial hierarchical structure, and truly reproduce the microscopic pathological characteristics of tumors. Moreover, the organoids can be stably subcultured for a long time, and provide an ideal and reliable preclinical model for the pathogenesis research, personalized drug screening and new therapy development of lung squamous carcinoma.

The present application relates to a kind of plasma markers GPNMB for predicting the curative effect of esophageal squamous cell carcinoma immunotherapy and its application, for screening predictive biomarker, we carry out plasma proteomics analysis, identify soluble glycoprotein non-metastatic melanoma protein B (sGPNMB) as the most significant circulating protein in treatment non-response patient is elevated, and through experiment determines, in humanized PDX model, the level of circulating GPNMB can predict PD-1 blocking curative effect, and inhibition GPNMB can enhance treatment effect.The method of the present application can realize the stratified management of esophageal squamous cell carcinoma patient, before carrying out immunotherapy, the plasma GPNMB level of patient is detected, can predict the subsequent treatment effect, and then screen out the patient suitable for immunotherapy and carry out treatment, ensure treatment effect, for the patient who is not suitable for immunotherapy can select other treatment scheme, realize the targeted effective treatment of different patients.

The present application relates to the technical field of biological medicine, and more particularly to the application of paraisodavid saponin II as an immunogenic cell death inducer in the treatment of esophageal squamous cell carcinoma. The present application first discloses and utilizes the key active monomer component of traditional Chinese medicine paris polyphylla var. chinensis, paraisodavid saponin II, and a novel biological function of the component in inducing immunogenic cell death of esophageal squamous cell carcinoma cells, and develops a corresponding drug application scheme based on the function. PPII converts "cold" tumors into "hot" tumors by inducing ICD, thereby enhancing the therapeutic effect of immune checkpoint inhibitors such as PD-1.

The application discloses a pharmaceutical use of linopteridin and a medicine containing the linopteridin. The use is that the linopteridin is applied to preparing a TBK1 inhibitor, and the TBK1 inhibitor combined with an anti-PD-1 antibody is applied to preparing a medicine for treating lung squamous carcinoma. The medicine is a TBK1 inhibitor containing the linopteridin, and a medicine composition containing the linopteridin and the anti-PD-1 antibody. The linopteridin can directly combine and inhibit the TBK1 kinase activity, and reduce the TBK1 phosphorylation level. The linopteridin combined with the anti-PD-1 antibody can significantly inhibit the lung squamous carcinoma tumor growth and has good safety. The aspect provides a new drug administration approach for treating the lung squamous carcinoma.